MedTrace Logo

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

NCT00959218 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2012-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

Conditions

  • Central Neuropathic Pain in Multiple Sclerosis

Interventions

DRUG

Dronabinol

oral solution, daily dose up to 15 mg, treatment up to 2.5 years

DRUG

Placebo

oral solution

Sponsors & Collaborators

  • Bionorica Research GmbH

    lead INDUSTRY

Principal Investigators

  • Sebastian Schimrigk, MD · Klinikum Luedenscheid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959218 on ClinicalTrials.gov